Actively Recruiting
Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial
Led by The Second Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-27
284
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
T
The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor
P
People's Hospital of Chongqing
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.
CONDITIONS
Official Title
Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia
- Aged 18 years or older
- Body mass index (BMI) between 18 and 30 kg/m2
- American Society of Anesthesiology (ASA) physical status I-III
- Understand the study details and willing to follow the protocol
- Provide voluntary informed consent
You will not qualify if you...
- Severe cardiovascular or cerebrovascular diseases such as myocardial infarction, unstable angina, severe heart rhythm disorders, or ischemic stroke
- Psychiatric disorders including schizophrenia or depression, or cognitive impairment
- Sensory disorders such as hyperalgesia
- Presence of other bodily pain
- Allergy to amide-type local anesthetics or study drugs
- Use of certain medications (liver metabolism-affecting drugs, corticosteroids, benzodiazepines, NSAIDs, opioid agonist-antagonists, central-alpha 2-agonists, anticonvulsants, antidepressants) within 72 hours
- History of alcohol or opioid abuse
- Pregnancy or lactation
- Participation in another clinical study within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 4000000
Actively Recruiting
Research Team
H
He Huang, ph.D
CONTACT
G
Guangyou Duan, ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here